ITUS Corporation (NYSE:ANIX) Expected to Post Earnings of -$0.13 Per Share

Wall Street brokerages predict that ITUS Corporation (NYSE:ANIX) will report earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ITUS’s earnings. ITUS reported earnings per share of ($0.23) during the same quarter last year, which indicates a positive year over year growth rate of 43.5%. The business is expected to issue its next earnings results on Wednesday, March 11th.

According to Zacks, analysts expect that ITUS will report full year earnings of ($0.49) per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of ($0.47) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for ITUS.

Several brokerages have commented on ANIX. Zacks Investment Research raised ITUS from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, January 1st. B. Riley cut their price target on ITUS from $11.25 to $8.00 and set a “buy” rating for the company in a report on Monday, December 30th.

In other news, Director Arnold M. Baskies bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $3.74 per share, with a total value of $37,400.00. Following the completion of the transaction, the director now directly owns 21,000 shares in the company, valued at $78,540. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amit Kumar bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were purchased at an average cost of $2.99 per share, for a total transaction of $59,800.00. Following the completion of the transaction, the chief executive officer now owns 194,000 shares of the company’s stock, valued at $580,060. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 37,400 shares of company stock valued at $121,620.

NYSE:ANIX traded up $0.04 during mid-day trading on Friday, hitting $3.27. 32,012 shares of the company’s stock traded hands, compared to its average volume of 57,732. The firm has a 50 day moving average of $3.45 and a two-hundred day moving average of $3.71. ITUS has a 12 month low of $2.74 and a 12 month high of $5.47.

ITUS Company Profile

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

Featured Article: Quantitative Easing

Get a free copy of the Zacks research report on ITUS (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.